Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

NCT: NCT03856658 · ACTIVE_NOT_RECRUITING

NCT IDNCT03856658
StatusACTIVE_NOT_RECRUITING
Start Date2019-02-05
Completion2028-12
SponsorCorewell Health West (OTHER)
First posted
Last updated

Brief Summary

This is a single arm, phase II study without blinding. The purpose is to determine the impact of hepatic artery infusion Floxuridine (FUDR) on liver metastases from pancreatic adenocarcinoma. Patients at Spectrum Health will receive standard of care chemotherapy. They will also receive chemotherapy via surgically placed hepatic artery infusion (HAI) pump.

Frequently Asked Questions

What is Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases?

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases is a clinical trial registered under NCT03856658. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT03856658?

The current status of NCT03856658 (Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases) is: ACTIVE_NOT_RECRUITING.

When did Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases start?

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases started on 2019-02-05.

Related Devices

K230022Baxter SIGMA Spectrum Infusion Pump with Master Drug LibraryBaxter Healthcare Corporation K251640SIGMA Spectrum Infusion Pump with Master Drug LibraryBaxter Healthcare Corporation

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑